Table 1 Clinicopathological characteristics of NSCLC patients based on the EZH2 expression in TCGA and TJMUGH cohort
From: EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
LUAD in TCGA cohort (n = 352) | LUAD in TJMUGH cohort (n = 16) | LUSC in TCGA cohort (n = 409) | LUSC in TJMUGH cohort (n = 24) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristics | Low EHZ2 level (n = 176) | High EHZ2 level (n = 176) | X2 test (P-value) | Low EHZ2 level (n = 8) | High EHZ2 level (n = 8) | X2 test (P-value) | Low EZH2 level (n = 205) | High EHZ2 level (n = 204) | X2 test (P-value) | Low EZH2 level (n = 12) | High EHZ2 level (n = 12) | X2 test (P-value) |
Age (%) | ||||||||||||
≤ 65 | 73 (41.5) | 93 (52.8) | 0.098 | 4 (50) | 2 (25) | 0.608 | 84 (41.0) | 77 (37.7) | 0.225 | 5 (41.7) | 10 (83.3) | 0.089 |
> 65 | 97 (55.1) | 79 (44.9) | 4 (50) | 6 (75) | 120 (58.5) | 122 (59.8) | 7 (58.3) | 2 (16.7) | ||||
Unknown | 6 (3.4) | 4 (2.3) | 1 (0.5) | 5 (2.5) | ||||||||
Gender (%) | ||||||||||||
Male | 85 (48.3) | 90 (51.1) | 0.670 | 6 (75) | 4 (50) | 0.608 | 156 (76.1) | 149 (73.0) | 0.497 | 10 (83.3) | 11 (73.0) | 1.000 |
Female | 91 (51.7) | 86 (48.9) | 2 (25) | 4 (50) | 49 (23.9) | 55 (27) | 2 (16.7) | 1 (27) | ||||
T stage (%) | ||||||||||||
T1-T2 | 143 (81.3) | 125 (71.0) | 0.033 | 6 (75) | 6 (75) | 1.000 | 172 (83.9) | 162 (79.4) | 0.253 | 11 (91.7) | 8 (66.7) | 0.317 |
T3-T4 | 33 (16.5) | 51 (29.0) | 2 (25) | 2 (25) | 33 (16.1) | 42 (20.6) | 1 (8.33) | 4 (33.3) | ||||
Lymph node metastasis (%) | ||||||||||||
Without | 116 (65.9) | 106 (60.2) | 0.320 | 4 (50) | 4 (50) | 1.000 | 131 (63.9) | 129 (63.2) | 0.918 | 7 (58.3) | 8 (66.7) | 0.414 |
With | 60 (18.8) | 70 (39.8) | 4 (50) | 4 (50) | 74 (36.1) | 75 (36.8) | 5 (41.7) | 4 (33.3) | ||||
Distant metastasis (%) | ||||||||||||
No distant metastasis | 168 (95.5) | 162 (92) | 0.186 | 8 (100) | 8 (100) | 200 (97.6) | 203 (99.5) | 0.215 | 12 (100) | 12 (100) | ||
Distant organs metastasis | 8 (4.5) | 14 (8.0) | 5 (2.4) | 1 (0.5) | ||||||||
TNM stage (%) | ||||||||||||
I + II | 105 (96.3) | 108 (99.1) | 0.116 | 5 (62.5) | 5 (62.5) | 1.000 | 165 (80.5) | 167 (81.9) | 0.409 | 8 (66.7) | 7 (58.3) | 0.414 |
III + IV | 4 (3.7) | 1 (0.9) | 3 (37.5) | 3 (37.5) | 40 (19.5) | 37 (18.1) | 4 (33.3) | 5 (41.7) | ||||
Tumor recurrence (%) | ||||||||||||
With tumor | 34 (19.3) | 37 (21.0) | 0.733 | 2 (75) | 1 (12.5) | 1.000 | 45 (22.0) | 32 (15.7) | 0.240 | 4 (33.3) | 2 (16.7) | 0.640 |
Tumor free | 99 (56.3) | 102(58.0) | 6 (25) | 7 (87.5) | 99 (8.3) | 102 (50) | 8 (66.7) | 10 (83.3) | ||||
Unknown | 43 (24.4) | 37 (21.0) | 61 (29.8) | 70 (34.3) | ||||||||
Smoker history (%) | ||||||||||||
Never smokers | 26 (14.8) | 24 (13.6) | 0.012 | 5 (62.5) | 5 (62.5) | 0.619 | 7 (3.4) | 8 (3.9) | 0.963 | 5 (41.6) | 2 (16.7) | 0.371 |
Smokers | 139 (79) | 151 (85.8) | 3 (37.5) | 3 (37.5) | 192 (93.7) | 190 (93.1) | 7 (58.3) | 10 (83.3) | ||||
Unknown | 11(6.3) | 1(0.6) | 6 (2.9) | 6 (2.9) | ||||||||